# A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

> **NCT07310901** · PHASE1 · RECRUITING · sponsor: **Corbus Pharmaceuticals Inc.** · enrollment: 252 (estimated)

## Conditions studied

- Obese But Otherwise Healthy Participants

## Interventions

- **DRUG:** CRB-913
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07310901
- **Lead sponsor:** Corbus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2026-07-02
- **Final completion:** 2026-07-31
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310901, "A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07310901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*